Lupus patients with pulmonary involvement have a pro-inflammatory cytokines profile

Al-Mutairi, Sana; Al-Awadhi, Adel; Raghupathy, Raj; Al-Khawari, Hanaa; Sada, Prio N.; Al-Herz, Adeebah; Rawoot, Parvez

doi:10.1007/s00296-006-0268-3

Cited by 31 publications

(25 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The significant positive correlation between serum TNF-α and bFGF levels seen in the whole patient group and HRCT-negative subjects and the lack of similar correlation in HRCT-positive patients might support such hypothesis in the light of the role of bFGF in fibrosis [15]. The results concerning the level of TNF-α in our study differ from the earlier ones obtained by other authors who observed increased serum level of this factor in SLE patients [16,17] especially in SLE subjects with pulmonary involvement [17]. The demonstrated differences could be partially explained by lower disease activity in our patients (calculated on the day of blood sampling SLEDAI score was <10 or slightly higher) [18].…”

Section: Discussioncontrasting

confidence: 90%

Selected growth factors and diffusing capacity of the lung for carbon monoxide in patients with systemic lupus erythematosus

et al. 2009

View full text Add to dashboard Cite

The purpose of the study was to evaluate serum concentrations of selected growth factors and the diffusing capacity of the lung for carbon monoxide (DLCO) in 21 females treated for SLE. The control group consisted of 24 healthy women. Based on high-resolution computed tomography (HRCT), patients were allocated to a subgroup of 11 subjects (HRCT-negative) and a subgroup of 10 with pulmonary abnormalities (HRCT-positive). In HRCT-negative patients a significantly higher level of TNF-α as compared to the control was observed and positive correlation between TNF-α and bFGF was revealed in this subroup and in the total group of patients. DLCO was below the predicted value in 13 patients. No correlations between DLCO and growth factors concentrations were observed. DLCO reduction in asymptomatic, in respect to the respiratory system, SLE patients suggests a need for longterm monitoring of this parameter. The role of TNF-α in these patients requires further investigations.

show abstract

Section: Discussioncontrasting

confidence: 90%

Selected growth factors and diffusing capacity of the lung for carbon monoxide in patients with systemic lupus erythematosus

et al. 2009

View full text Add to dashboard Cite

show abstract

“…12 In terms of lung involvement only a few studies are available, suggesting that some of these markers can be elevated in blood and exhaled breath condensate of SLE patients with pulmonary manifestations. 13,14 Previous studies reported interleukin (IL)-6, IL-8, interferon-g (INF-g) and tumor necrosis factor-a (TNF-a) as possible markers for pulmonary manifestation in SLE patients. 13,15 However, these markers are not specific enough to identify the pulmonary manifestations, as their levels are elevated in many pathophysiological conditions.…”

Section: Introductionmentioning

confidence: 99%

“…13,14 Previous studies reported interleukin (IL)-6, IL-8, interferon-g (INF-g) and tumor necrosis factor-a (TNF-a) as possible markers for pulmonary manifestation in SLE patients. 13,15 However, these markers are not specific enough to identify the pulmonary manifestations, as their levels are elevated in many pathophysiological conditions.…”

Section: Introductionmentioning

confidence: 99%

CCL21 and IP-10 as blood biomarkers for pulmonary involvement in systemic lupus erythematosus patients

Odler

Bikov

Streizig

et al. 2016

Lupus

View full text Add to dashboard Cite

Biomarkers for pulmonary manifestations in systemic lupus erythematosus (SLE) are missing. Plasma samples of nine SLE patients with known pulmonary involvement (SLE pulm ) and nine SLE patients without pulmonary involvement (SLE) were tested by multiplex microarray analysis for various cyto-and chemokines. Significantly decreased lung function paramters for forced vital capacity (FVC), total lung capacity (TLC), diffusion capacity for carbon monoxide (DL CO ) and diffusion of CO corrected on lung volume (KL CO ) were observed in SLE pulm as compared to SLE patients. CC chemokine ligand 21 (CCL21) and interferon gamma-induced protein 10 (IP-10) levels were significantly higher in SLE pulm , than in patients without pulmonary manifestations. CCL21 correlated negatively with DL CO (r ¼ À0.73; p < 0.01) and KL CO (r ¼ À0.62; p < 0.01), while IP-10 with FVC and forced expiratory volume one second. Receiver Operating Characteristics (ROC) analysis confirmed high sensitivity and specificity for the separation of SLE patients with and without pulmonary involvement for the chemokines CCL21 (Area Under Curve (AUC): 0.85; sensitivity%: 88.90; specificity%: 75.00; p < 0.01) and IP-10 (AUC: 0.82; sensitivity%: 66.67, specificity%: 100; p < 0.01). Pleuropulmonary manifestations in SLE patients associated with lung functional and DL CO /KL CO changes and were associated with significant increase in CCL21 and IP-10. These chemokines might serve as potential biomarkers of lung involvement in SLE patients. Lupus (2016) 0, 1-8.

show abstract

“…Al-Mutairi et al 13 reported that proinflammatory cytokines (tumor necrosis factor, interferon-γ, IL-8) were more prevalent in the serum of patients with pulmonary involvement compared with those without pulmonary manifestations. However, the serum levels of IL-10 were similar in the pulmonary and nonpulmonary phenotypes.…”

Section: Methodsmentioning

confidence: 99%

Exhaled cytokines in systemic lupus erythematosus with lung involvement

Nielepkowicz-Goździńska¹,

Fendler²,

Robak³

et al. 2013

Polish Archives of Internal Medicine

View full text Add to dashboard Cite

Lupus patients with pulmonary involvement have a pro-inflammatory cytokines profile

Abstract: Lupus patients with pulmonary involvement have a stronger pro-inflammatory cytokine bias than those without pulmonary involvement.

Cited by 31 publications

References 40 publications

Selected growth factors and diffusing capacity of the lung for carbon monoxide in patients with systemic lupus erythematosus

Selected growth factors and diffusing capacity of the lung for carbon monoxide in patients with systemic lupus erythematosus

CCL21 and IP-10 as blood biomarkers for pulmonary involvement in systemic lupus erythematosus patients

Exhaled cytokines in systemic lupus erythematosus with lung involvement

Contact Info

Product

Resources

About